Australian-Singaporean regenerative medicine company Osteopore (ASX: OSX) has secured an exclusive licensing agreement with Accelerate for a pioneering Heparan Sulphate bioactive technology platform designed to accelerate bone and tissue regeneration.
Osteopore, a global leader in 3D-printed biomimetic and bioresorbable implants, has been collaborating with the Institute of Molecular and Cell Biology, A*STAR Research Entities, to integrate various Heparan Sulphate molecules into its proprietary implant technology.
The combination has the potential to significantly improve both the speed and quality of bone regeneration, potentially reducing recovery times, lowering complication rates, and enhancing overall patient outcomes.
In April 2024, Osteopore initiated a human clinical trial at the National University Hospital Singapore, combining Heparan Sulphate 3—a molecule targeting bone morphogenetic protein-2—with Osteopore’s approved implant for medial wedge opening high tibial osteotomy in up to 12 patients. The study is currently ongoing.